Lb Pharmaceuticals INC 10-Q quarterly reports

LB Pharmaceuticals Inc. reported a substantial increase in research and development expenses and a widening net loss for the second quarter of 2026, driven by ongoing clinical trials for its lead product candidate, LB-102.

LB Pharmaceuticals Inc. announced its first-quarter 2026 financial results, highlighting progress in its clinical development programs for LB-102 and a strong cash position.

LB Pharmaceuticals Inc. successfully completed its initial public offering, raising $302.3 million net, significantly bolstering its cash position to fund operations into Q2 2028 while progressing its lead drug candidate, LB-102, into Phase 3 for schizophrenia and Phase 2 for bipolar depression.